Lobucavir

Lobucavir

SCHEMBL598707

Nc1nc2c(ncn2[C@@H]2CC(CO)C2CO)c(=O)[nH]1

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPRT1 P00492 3/20 0.53
ADORA3 P0DMS8 1/20 0.53
PNP P00491 4/20 0.52
TK1 P04183 2/20 0.49
AHCY P23526 2/20 0.48
BLM P54132 2/20 0.47
USP2 O75604 1/20 0.47
TSHR P16473 1/20 0.47
EDNRA P25101 1/20 0.47
HTR2A P28223 1/20 0.47
RECQL P46063 1/20 0.47
HBB P68871 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
CYP3A4 P08684 1/20 0.46
NFKB1 P19838 1/20 0.46
VCP P55072 1/20 0.46
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lobucavir SCHEMBL5990162 1.00 HPRT1 (0.53) HPRT1ADORA3PNPTK1AHCY
Lobucavir SCHEMBL10460499 1.00 HPRT1 (0.53) HPRT1ADORA3PNPTK1AHCY
Lobucavir SCHEMBL51919 1.00 HPRT1 (0.53) HPRT1ADORA3PNPTK1AHCY
Lobucavir SCHEMBL418430 1.00 HPRT1 (0.53) HPRT1ADORA3PNPTK1AHCY
Lobucavir SCHEMBL9615453 1.00 HPRT1 (0.53) HPRT1ADORA3PNPTK1AHCY
Lobucavir SCHEMBL9615451 1.00 HPRT1 (0.53) HPRT1ADORA3PNPTK1AHCY
Lobucavir SCHEMBL15630215 1.00 HPRT1 (0.53) HPRT1ADORA3PNPTK1AHCY
Lobucavir SCHEMBL51918 1.00 HPRT1 (0.53) HPRT1ADORA3PNPTK1AHCY
Lobucavir SCHEMBL7699733 1.00 HPRT1 (0.53) HPRT1ADORA3PNPTK1AHCY
Lobucavir SCHEMBL7166488 1.00 HPRT1 (0.53) HPRT1ADORA3PNPTK1AHCY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8114994-B2 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment viral infections and abnormal cellular proliferation EMORY UNIVERSITY (US) 2012-02-14 US disclosed
US-20090149416-A1 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-06-11 US disclosed
US-7495006-B2 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation EMORY UNIVERSITY (US) 2009-02-24 US disclosed
US-20060223835-A1 2' and 3'- substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation EMORY UNIVERSITY 2006-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149416-A1 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation HAVCR2, PNP, PCNA HPRT1 4/4885ADORA3 790/4885PNP 2/4885
US-20060223835-A1 2' and 3'- substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation HAVCR2, PNP, DCTD HPRT1 5/4885ADORA3 780/4885PNP 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.